Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
ALDX Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ALDX Stock 12 Month Forecast
Average Price Target
$8.67
▲(90.97% Upside)
| Highest Price Target$10.00 | Average Price Target$8.67 | Lowest Price Target$7.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$10
Buy
120.26%
Upside
Reiterated
11/17/25
BTIG
$9
Buy
98.24%
Upside
Reiterated
11/13/25
Jefferies
$7
Buy
54.19%
Upside
Reiterated
10/08/25
Promising Developments and Strategic Partnerships Drive Buy Rating for Aldeyra TherapeuticsWe like ALDX as a platform story with near-term upside + pot'l future cash flow from ABBV. FDA acceptance of resubmitted NDA for Reproxalap will be a key inflection point and milestone for ALDX, in our view; PDUFA is set for Dec 16, 2025. The NDA resubmission follows positive results from a second dry eye chamber trial, which met its primary endpoint (note) and was designed to address concerns raised by the regulator in the CRL regarding baseline imbalances across treatment arms (note). Co also conducted a field trial that showed numerical benefits but did not hit stat sig. Mgmt commentary indicated the NDA package included only data from the latest chamber trial. We believe mgmt has been transparent about the general issues raised in CRL (link), and Co has diligently addressed FDA concerns (while details of stat method remain undisclosed).
Leerink Partners
$10
Buy
120.26%
Upside
Reiterated
08/12/25
JonesTrading
$6→$9
Buy
98.24%
Upside
Reiterated
08/08/25
Laidlaw
$11
Buy
142.29%
Upside
Reiterated
04/04/25
LifeSci Capital
$12
Buy
164.32%
Upside
Reiterated
03/03/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$10
Buy
120.26%
Upside
Reiterated
11/17/25
BTIG
$9
Buy
98.24%
Upside
Reiterated
11/13/25
Jefferies
$7
Buy
54.19%
Upside
Reiterated
10/08/25
Promising Developments and Strategic Partnerships Drive Buy Rating for Aldeyra TherapeuticsWe like ALDX as a platform story with near-term upside + pot'l future cash flow from ABBV. FDA acceptance of resubmitted NDA for Reproxalap will be a key inflection point and milestone for ALDX, in our view; PDUFA is set for Dec 16, 2025. The NDA resubmission follows positive results from a second dry eye chamber trial, which met its primary endpoint (note) and was designed to address concerns raised by the regulator in the CRL regarding baseline imbalances across treatment arms (note). Co also conducted a field trial that showed numerical benefits but did not hit stat sig. Mgmt commentary indicated the NDA package included only data from the latest chamber trial. We believe mgmt has been transparent about the general issues raised in CRL (link), and Co has diligently addressed FDA concerns (while details of stat method remain undisclosed).
Leerink Partners
$10
Buy
120.26%
Upside
Reiterated
08/12/25
JonesTrading
$6→$9
Buy
98.24%
Upside
Reiterated
08/08/25
Laidlaw
$11
Buy
142.29%
Upside
Reiterated
04/04/25
LifeSci Capital
$12
Buy
164.32%
Upside
Reiterated
03/03/25
Best Analysts Covering Aldeyra Therapeutics
1 Month
xxx
Success Rate
13/21 ratings generated profit
Average Return
+9.32%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.90% of your transactions generating a profit, with an average return of +9.32% per trade.
3 Months
xxx
Success Rate
15/25 ratings generated profit
Average Return
+21.34%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +21.34% per trade.
1 Year
Success Rate
9/14 ratings generated profit
Average Return
+31.39%
reiterated a buy rating 4 months ago
Copying Catherine Novack's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +31.39% per trade.
2 Years
xxx
Success Rate
8/14 ratings generated profit
Average Return
+24.45%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +24.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ALDX Analyst Recommendation Trends
Rating
Jun 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
11
9
7
4
4
Buy
2
1
0
1
1
Hold
0
0
0
0
0
Sell
2
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
10
7
5
5
Each month's total comprises the sum of three months' worth of ratings.
ALDX Financial Forecast
ALDX Stock Forecast FAQ
What is ALDX’s average 12-month price target, according to analysts?
Based on analyst ratings, Aldeyra Therapeutics’s 12-month average price target is 8.67.
What is ALDX’s upside potential, based on the analysts’ average price target?
Aldeyra Therapeutics has 90.97% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ALDX a Buy, Sell or Hold?
Aldeyra Therapeutics has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Aldeyra Therapeutics’s price target?
The average price target for Aldeyra Therapeutics is 8.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $7.00. The average price target represents 90.97% Increase from the current price of $4.54.
The highest analyst price target is $10.00 ,the lowest forecast is $7.00. The average price target represents 90.97% Increase from the current price of $4.54.
What do analysts say about Aldeyra Therapeutics?
Aldeyra Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of ALDX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.